In a seismic shift for American healthcare, President Donald Trump's revived Most Favored Nations (MFN) policy is slashing prescription drug prices by tying them to the lowest rates in other developed countries, promising billions in savings for patients and taxpayers. But as the administration secures landmark deals with major pharmaceutical giants, critics point to a history of Democratic resistance.

Important regional, state, and national news brought to readers in a concise format.